Haemonetics Corporation
HAE
$56.66
-$1.80-3.08%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.32B | 1.33B | 1.35B | 1.36B | 1.37B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.32B | 1.33B | 1.35B | 1.36B | 1.37B |
| Cost of Revenue | 530.31M | 545.65M | 567.25M | 594.60M | 617.51M |
| Gross Profit | 787.96M | 782.20M | 778.80M | 766.23M | 756.01M |
| SG&A Expenses | 422.65M | 422.47M | 427.40M | 428.83M | 427.26M |
| Depreciation & Amortization | 44.80M | 46.10M | 47.18M | 48.26M | 47.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.06B | 1.07B | 1.10B | 1.13B | 1.15B |
| Operating Income | 261.82M | 253.39M | 244.35M | 230.39M | 222.93M |
| Income Before Tax | 227.17M | 217.11M | 210.53M | 212.07M | 164.75M |
| Income Tax Expenses | 51.73M | 48.92M | 47.19M | 44.39M | 34.68M |
| Earnings from Continuing Operations | 175.44 | 168.19 | 163.34 | 167.68 | 130.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 175.44M | 168.19M | 163.34M | 167.68M | 130.07M |
| EBIT | 261.82M | 253.39M | 244.35M | 230.39M | 222.93M |
| EBITDA | 367.72M | 360.94M | 352.86M | 339.28M | 329.35M |
| EPS Basic | 3.65 | 3.44 | 3.30 | 3.34 | 2.56 |
| Normalized Basic EPS | 2.95 | 2.76 | 2.60 | 2.58 | 2.55 |
| EPS Diluted | 3.64 | 3.43 | 3.28 | 3.32 | 2.54 |
| Normalized Diluted EPS | 2.93 | 2.75 | 2.58 | 2.56 | 2.53 |
| Average Basic Shares Outstanding | 191.69M | 195.18M | 198.49M | 201.32M | 202.91M |
| Average Diluted Shares Outstanding | 192.48M | 196.13M | 199.71M | 202.92M | 204.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |